STAT July 5, 2024
New research finds that the GLP-1 class of drugs — glucagon-like peptide receptor agonists — is more effective in mitigating the risk of 10 obesity-associated cancers than its type 2 diabetes drug alternatives.
The retrospective study, published Friday in JAMA Network Open, measured results for a cohort of more than 1.6 million patients with type 2 diabetes from 2005 to 2018 who were prescribed...